Psoriatic Arthritis & Ankylosing Spondylitis
Home / Psoriatic Arthritis & Ankylosing Spondylitis
Psoriatic Arthritis & Ankylosing Spondylitis
These spondyloarthropathies benefit from:
- IL-17 inhibitors (secukinumab, ixekizumab)
- IL-23 inhibitors (guselkumab, risankizumab)
- TNF blockade remains foundational for axial disease
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries